KRAS and non-small cell lung carcinoma: The randomized phase III SELECT-1 trial has compared selumetinib plus docetaxel versus docetaxel in 510 patients with KRAS mutant pretreated NSCLC, showing no significant difference in mPFS (3.9 vs 2.8 months, p=0.44) and mOS (8.7 vs 7.9 months, p=0.64) (86).